Results 31 to 40 of about 825,301 (311)

Identification of recent cases of hepatitis C virus infection using physical-chemical properties of hypervariable region 1 and a radial basis function neural network classifier

BMC Genomics, 2017
Background Identification of acute or recent hepatitis C virus (HCV) infections is important for detecting outbreaks and devising timely public health interventions for interruption of transmission.
James Lara, Mahder Teka, Yury Khudyakov
doaj   +1 more source

P-70 HEPATITIS B IMMUNITY AMONG CHRONIC RENAL DISEASE UNDER HEMODIALYSIS

Annals of Hepatology, 2023
Introduction and Objectives: Hepatitis B Virus (HBV) has been a cause of acute and chronic hepatitis with progression to cirrhosis and hepatocellular carcinoma.
Alanna Calheiros Santos, Juliana Gil Melgaço, Lucas Lima da Silva, Vanessa Duarte da Costa, Juliana Custódio Miguel, Elisangela Ferreira da Silva, Julia Trece Marques, Giselle Prado do Nascimento, Vanessa Salete de Paula, Livia Melo Villar   +9 more
doaj   +1 more source

Hepatitis C and hepatic steatosis [PDF]

QJM, 2010
Hepatic steatosis is commonly seen in patients with chronic hepatitis C infection, and the two together have a greater association than by chance alone. Hepatitis C virus is closely associated with lipid metabolism throughout its lifecycle. Hepatic steatosis is more common in genotype 3 infection, due to direct viral effects including through ...
J H, Patel, J F L, Cobbold, H C, Thomas, S D, Taylor-Robinson   +3 more
openaire   +2 more sources

Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance.

, 2004
We examined correlates of antinuclear antibody (ANA) positivity (ANA+) in individuals with chronic hepatitis C virus (HCV) infection and the effect of positivity on clinical outcome of HCV. Pretreatment sera from 645 patients from three centres in Sweden
Marshall, S, Goldin, RD, A. Alberti, A. J. Hall, Yee, LJ, Thomas, HC, Thursz, MR, Chiaramonte, M, Braconier, J-H, Hall, AJ, L. J. Yee, H. C. Thomas, Braconier, Jean Henrik, R. D. Goldin, M. Chiaramonte, M. R. Thursz, S. Marshall, Kelleher, P, Braconier, Jean Henrik,, Alberti, A, Lund University., J.‐H. Braconier, P. Kelleher   +22 more
core   +1 more source

Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery

Harm Reduction Journal, 2023
Background The World Health Organization (WHO) recommends oral pre-exposure prophylaxis (PrEP) for all people at substantial risk of HIV as part of combination prevention.
Graham Shaw, Robin Schaefer, Heather-Marie A Schmidt, Annie Madden, Judy Chang, Antons Mozalevskis, Busisiwe Msimanga-Radebe, Nabeel Mangadan Konath, Annette Verster, Rachel Baggaley, Michelle Rodolph, Virginia Macdonald   +11 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Best practices for engaging with affected communities: chronic hepatitis B as a case study

Infectious Diseases of Poverty
Hepatitis B is the single most common cause of liver cancer, affecting > 250 million people worldwide (mostly in resource limited communities) and killing > 1 million people annually. The condition is marked by poor rates of diagnosis (14%) and treatment
Thomas Tu, Nafisa Yussf, Lien Tran, Kim Ngo, Su Wang, Adi Mondel, Isabelle Purcell, Jacki Chen, Wendy Lo, Bright Ansah, Kenneth Kabagambe, Soumen Basu, Dee Lee, Supa Chantschool, Chris Munoz, Ivana Dragojevic, Marko Korenjak, Fiona Borondy-Jenkins, Yasmin Ibrahim, Beatrice Zovich, Chari Cohen   +20 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Identifying barriers to hepatitis B and delta screening, prevention, and linkage to care among people who use drugs in Philadelphia, Pennsylvania, USA

Harm Reduction Journal
Background People who use drugs (PWUD) are at increased risk for blood-borne viruses, including hepatitis B (HBV) and delta (HDV). Despite the public health threats both viruses present, awareness remains low among at-risk communities and providers who ...
Beatrice Zovich, Catherine Freeland, Holly Moore, Kara Sapp, Anousha Qureshi, Amy Jessop, Rachel Holbert, Fiona Borondy-Jenkins, Quinn Plunkett, Chari Cohen   +9 more
doaj   +1 more source

Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada

BMJ Open
Objectives To collect and document the numerous barriers that people living with hepatitis B (PLHB) encounter when trying to access their hepatitis B virus (HBV) medications.Design Researchers collected qualitative data through 24 online interviews.
Sophie Jacob, Michaela Jackson, Yasmin Ibrahim, Catherine Freeland, Beatrice Zovich, Chari Cohen   +5 more
doaj   +1 more source